Vivos Inc (OTC: RDGL) is engaged in the development of a brachytherapy device for the treatment of cancerous tumors. Brachytherapy uses radiation to destroy tumors by placing a radioactive isotope inside the treatment area. Currently, the company is pursuing FDA approval of its brachytherapy device, RadioGel, initially for the treatment of advanced basal and squamous skin cancers. Concurrently, the Company is pursuing development of veterinary applications for a range of cancers in collaboration with four leading university veterinary hospitals. Veterinary applications should have a faster path to revenue for RDGL, while providing data supporting the safety and therapeutic effectiveness of RadioGel. RDGL’s RadioGel requires no pre-market approval for pet therapy and the Company plans to generate near term revenue from veterinarian clinics and international licensing by 1Q18.

 

• Plans to generate near-term revenue from veterinarian clinics and international licensing by 1Q18
  • RDGL is in late-stage development of a brachytherapy device for medical and veterinary cancer treatment applications

• Company has the potential to disrupt the cancer treatment market with lower cost and shorter approval path of a cancer treatment device
  • Brachytherapy market is expected to reach $245 million by 2018
  • RDGL’s next-generation radiopharmaceutical therapeutic device uses hydrogel that is liquid at room temperature and solidifies at body temperate and locks in the particles

• Company’s RadioGel requires no pre-market approval for pet therapy
  • Cancer is the leading cause of death for 32% of cats and 50% of dogs over age 10
  • Treating 10% of pet cancers at $5,000 average per treatment, generates $40 million annual revenue
  • Currently testing at leading university veterinary programs to demonstrate therapy across multiple indications

• Strong leadership and word-class medical advisory board
  • More than 125 years combined experience; input from Mayo Clinic doctors